Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

COVID-19

R&D

RADIOPROLIQ. Molecular signature in liquid biopsy for response to radiotherapy and early relapse in prostate cancer

In this project, a molecular signature based on genomics and metabolomics will be developed from liquid biopsies. This signature will allow to predict the response to radiotherapy and early relapse in patients with prostate cancer undergoing external radiotherapy (SBRT and IMRT).

Prostate cancer is the second most common cancer among men with 1.28 million cases diagnosed in 2018 in the world, 88.4% of which are diagnosed in developed countries. It is the sixth leading cause of cancer death in men, with the highest mortality in developing countries, and much higher morbidity in developed countries thanks to the extension of diagnostic methods and early detection.

Results obtained in this project will allow to predict the response to therapy, as well as to detect early relapse in prostate cancer.

To achieve the objectives of the project, a consortium has been set up to guarantee technological success and subsequent commercial exploitation. The project is led by the Red Hospitalaria Recoletas and has the support of the Salamanca Biomedical Research Institute (IBSAL), the Medina Foundation and Atrys Health.

This project has been funded by the Ministry of Science, Innovation and Universities within the RETOS-COLABORACIÓN Subprogram, Call 2019. The project is co-financed by the European Union with the aim of promoting technological development, innovation and quality research.

Project ID: RTC2019-007357-1

2020-2023